key: cord-0756915-oyieushf
authors: Bensussen, Antonio; Valcarcel, Antonio; Álvarez-Buylla, Elena R.; Díaz, José
title: ORF8 and Health Complications of COVID-19 in Down Syndrome Patients
date: 2022-02-09
journal: Front Genet
DOI: 10.3389/fgene.2022.830426
sha: 0388a2d51997ff85c2019eaee48d2d70d47b811f
doc_id: 756915
cord_uid: oyieushf

nan

FIGURE 1 | Down syndrome patients have higher levels of ORF8 during SARS-COV-2 infection. (A) Once the SARS-CoV-2 ACE2-Spike complexes enter the cells (IC), the production of genomic RNA (gRNA) originates ORF8 antigens by several editing steps. These copies of ORF8 may be naturally degraded or eliminated by antibodies. (A) The simplified model of ORF8 production used in this work. In the model k 1 = 0.4 days −1 , s 1 = 100 days −1 , k 2 = 1.3 days −1 , s 2 = 20 days −1 , k ab = 0.3 days −1 , and k 1/2 = 0.5 days −1 . (B) Mean levels of ORF8 obtained from the model simulations at 2, 4, 6, 30, and 40 days. These results suggest that ORF8 persists even if the patient is discharged 15 days after viral onset. (C) Effect of the presence of an extra copy of TMPRSS2. These simulations show that an extra copy of TMPRSS2 gene is able to dramatically increase systemic levels of ORF8, which implies that Down syndrome patients are more susceptible to medical complications produced by ORF8.

Frontiers in Genetics | www.frontiersin.org February 2022 | Volume 13 | Article 830426

Sars-CoV-2 (Covid-19) by the Numbers

In Silico discovery of Antigenic Proteins and Epitopes of SARS-CoV-2 for the Development of a Vaccine or a Diagnostic Approach for COVID-19

What People with Down Syndrome Can Teach Us about Cardiopulmonary Disease

Network Analysis of Down Syndrome and SARS-CoV-2 Identifies Risk and Protective Factors for COVID-19

Down Syndrome and COVID-19: A Perfect Storm?

Protective Role of Nitric Oxide against Cardiac Arrhythmia -an Update

ORF8 and ORF3b Antibodies Are Accurate Serological Markers of Early and Late SARS-CoV-2 Infection

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Medical Vulnerability of Individuals with Down Syndrome to Severe COVID-19-Data from the Trisomy 21 Research Society and the UK ISARIC4C Survey

Broad and strong Memory CD4+ and CD8+ T Cells Induced by SARS-CoV-2 in UK Convalescent Individuals Following COVID-19

Structural Analysis of SARS-CoV-2 ORF8 Protein: Pathogenic and Therapeutic Implications

The Interferons and Their Receptors-Distribution and Regulation

Virological Assessment of Hospitalized Patients with COVID-2019

The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Down-Regulating MHC-Ι

AB and AV have contributed equally to this work and share first authorship. AB made the in silico analysis of the model. All authors participated equally in the writing of the manuscript.

AB and AV thank CONACYT for the postdoctoral fellowship. We thank Erika Juarez Luna for her logistical support.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The model we used in this work takes into account the levels of the Spike-ACE2-TMPRSS2 complex (IC) that allows the internalization of the SARS-CoV-2 genomic RNA (gRNA) and the systemic levels of ORF8. To model ORF8 systemic levels, we considered the half-life of the protein (Can et al., 2020) as well as the effect of neutralizing antibodies against ORF8 (Hachim et al., 2020) (Figure 1A) . Next, we used ex vivo data obtained from COVID-19 patients (Bar-On et al., 2020; Hachim et al., 2020; Peng et al., 2020; Wölfel et al., 2020) to estimate parameters and to calibrate the model congruently with previous observations (Peng et al., 2020) . The model was numerically solved using the Runge-Kutta 4-5 method and MATLAB software.Frontiers in Genetics | www.frontiersin.org February 2022 | Volume 13 | Article 830426